IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-31839-7.html
   My bibliography  Save this article

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil

Author

Listed:
  • Thiago Cerqueira-Silva

    (Instituto Gonçalo Moniz, Fiocruz
    Universidade Federal da Bahia)

  • Vinicius Araujo Oliveira

    (Universidade Federal da Bahia
    Instituto Gonçalo Moniz, Fiocruz)

  • Enny S. Paixão

    (London School of Hygiene and Tropical Medicine)

  • Juracy Bertoldo Júnior

    (Universidade Federal da Bahia
    Instituto Gonçalo Moniz, Fiocruz)

  • Gerson O. Penna

    (Universidade de Brasília. Escola Fiocruz de Governo)

  • Guilherme L. Werneck

    (Universidade do Estado do Rio de Janeiro
    Universidade Federal do Rio de Janeiro)

  • Neil Pearce

    (London School of Hygiene and Tropical Medicine)

  • Maurício L. Barreto

    (Universidade Federal da Bahia
    Instituto Gonçalo Moniz, Fiocruz)

  • Viviane S. Boaventura

    (Instituto Gonçalo Moniz, Fiocruz
    Universidade Federal da Bahia)

  • Manoel Barral-Netto

    (Instituto Gonçalo Moniz, Fiocruz
    Universidade Federal da Bahia)

Abstract

To date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine effectiveness (VE) of CoronaVac plus BNT162b2 booster during the period of dominance of the Omicron variant in Brazil (January to April 2022). Using a test-negative design, we analysed data for 2,471,576 individuals tested during the Omicron variant’s dominant period using a nationally linked database from Brazil. Compared to unvaccinated, vaccinees maintained protection against severe outcomes, with an estimated VE of 84.1% (95% CI:83.2–84.9) at more than 120 days after BNT162b2 booster. Furthermore, while we detected a high level of protection against severe outcomes for individuals up to 79 years old, waning was observed for individuals aged ≥80 years, with VE decreasing from 81.3% (95% CI:77.9–84.2) at 31–60 days to 72.9% (95% CI:70.6–75.1) at 120 days or more after the booster dose. However, no significant protection against symptomatic infection was observed at this time period. In conclusion, except for individuals aged ≥80 years, CoronaVac plus a BNT162b2 booster dose offered high and durable protection against severe outcomes due to Omicron.

Suggested Citation

  • Thiago Cerqueira-Silva & Vinicius Araujo Oliveira & Enny S. Paixão & Juracy Bertoldo Júnior & Gerson O. Penna & Guilherme L. Werneck & Neil Pearce & Maurício L. Barreto & Viviane S. Boaventura & Manoe, 2022. "Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil," Nature Communications, Nature, vol. 13(1), pages 1-6, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31839-7
    DOI: 10.1038/s41467-022-31839-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-31839-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-31839-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Roxana Manuela Fericean & Cristian Oancea & Akash Reddy Reddyreddy & Ovidiu Rosca & Felix Bratosin & Vlad Bloanca & Cosmin Citu & Satish Alambaram & Neeharika Gayatri Vasamsetti & Catalin Dumitru, 2023. "Outcomes of Elderly Patients Hospitalized with the SARS-CoV-2 Omicron B.1.1.529 Variant: A Systematic Review," IJERPH, MDPI, vol. 20(3), pages 1-11, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-31839-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.